Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 01 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Usnoflast is currently under clinical development for several indications, including rare autoinflammatory diseases and neurological conditions. This press release serves to inform investors and the exchange about this significant development in Zydus Lifesciences' research efforts.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 01, 2024, titled "Zydus Lifesciences receives approval for the name Usnoflast as recommended name for ZYIL1 from the WHO International Non-proprietary Names (INN) .

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases